GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Trinity Biotech PLC (NAS:TRIB) » Definitions » EV-to-EBITDA

Trinity Biotech (Trinity Biotech) EV-to-EBITDA : -2.84 (As of Apr. 25, 2024)


View and export this data going back to 1995. Start your Free Trial

What is Trinity Biotech EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Trinity Biotech's enterprise value is $74.74 Mil. Trinity Biotech's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 was $-26.34 Mil. Therefore, Trinity Biotech's EV-to-EBITDA for today is -2.84.

The historical rank and industry rank for Trinity Biotech's EV-to-EBITDA or its related term are showing as below:

TRIB' s EV-to-EBITDA Range Over the Past 10 Years
Min: -189.89   Med: 12.31   Max: 534.08
Current: -2.84

During the past 13 years, the highest EV-to-EBITDA of Trinity Biotech was 534.08. The lowest was -189.89. And the median was 12.31.

TRIB's EV-to-EBITDA is ranked worse than
100% of 117 companies
in the Medical Diagnostics & Research industry
Industry Median: 15.81 vs TRIB: -2.84

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-25), Trinity Biotech's stock price is $1.83. Trinity Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 was $-3.740. Therefore, Trinity Biotech's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Trinity Biotech EV-to-EBITDA Historical Data

The historical data trend for Trinity Biotech's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trinity Biotech EV-to-EBITDA Chart

Trinity Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.15 -5.80 79.16 11.52 -7.28

Trinity Biotech Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -9.45 -7.28 -6.51 -3.03 -3.37

Competitive Comparison of Trinity Biotech's EV-to-EBITDA

For the Diagnostics & Research subindustry, Trinity Biotech's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech's EV-to-EBITDA Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Trinity Biotech's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's EV-to-EBITDA falls into.



Trinity Biotech EV-to-EBITDA Calculation

Trinity Biotech's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=74.738/-26.34
=-2.84

Trinity Biotech's current Enterprise Value is $74.74 Mil.
Trinity Biotech's EBITDA for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-26.34 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Trinity Biotech  (NAS:TRIB) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Trinity Biotech's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=1.83/-3.740
=At Loss

Trinity Biotech's share price for today is $1.83.
Trinity Biotech's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.740.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Trinity Biotech EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Trinity Biotech's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Trinity Biotech (Trinity Biotech) Business Description

Traded in Other Exchanges
Address
IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of development, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point of care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Premier, Immublot, EZ, Capita, and others. Geographically, it has two segments namely the Americas, and Rest of World - Ireland of which it derives a majority of its revenues from the Americas segment.